Xanthine oxidase-IN-18

Xanthine oxidase-IN-18 is a potent orally activeXanthine oxidase (XO) inhibitor (IC50 = 0.263 μM) . Xanthine oxidase-IN-18 exerts inhibition by directly and stably binding to the xanthine oxidase Mo-co active site. Xanthine oxidase-IN-18 exhibits reactive oxygen species (ROS) scavenging activity. Xanthine oxidase-IN-18 shows anti-hyperuricemia effects in a Potassium oxonate (HY-17511) -induced hyperuricemic rat model. Xanthine oxidase-IN-18 can be used for hyperuricemia, breast and lung cancer research[1].

Product Specifications

UNSPSC

12352005

Target

Reactive Oxygen Species (ROS) ; SOD; Xanthine Oxidase

Related Pathways

Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Inflammation/Immunology; Metabolic Disease

Smiles

C/C=C/C1=CC=C(OCC2=CN(CCCOC3=CC=C(OCO4)C4=C3)N=N2)C(OC)=C1

Molecular Formula

C23H25N3O5

Molecular Weight

423.46

References & Citations

[1]Singh K, et al. Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan-Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy. ACS Med Chem Lett. 2025 Sep 17;16 (10) :1986-1996.